Menu

Blog

May 19, 2020

7 New Insights about the Frontrunner U.S. Vaccine Candidate

Posted by in categories: biotech/medical, government

U.S. National Institute of Allergy and Infectious Diseases Director Anthony Fauci called the vaccine’s preclinical data “impressive” and told National Geographic this week that a vaccine could be ready for general use as early as January.

The Phase I trial has dosed 45 healthy adults. Phase II trials are about to start, enrolling around 600 adults. Pivotal efficacy trials would follow soon thereafter, bankrolled in collaboration with the government office BARDA (Biomedical Advanced Research and Development Authority).

Today, the chief medical officer of Moderna, Tal Zaks, answered burning questions from the public in a webinar hosted by STAT. Here’s an edited and condensed summary of his answers.

Comments are closed.